Asymptomatic Myeloma Prognosis

Loading...

References

  1. Meletios A Dimopoulos. Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.. The New England journal of medicine, 2025
  2. Ioannis Ntanasis-Stathopoulos. Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies.. Blood cancer journal, 2025
  3. Ola Landgren. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma.. Blood, 2024
  4. H. Ludwig. SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis. eClinicalMedicine, 2023
  5. Mark Bustoros. Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.. Nature communications, 2022
  6. M A Dimopoulos. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.. Annals of oncology : official journal of the European Society for Medical Oncology, 2021
  7. M. Mateos. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer Journal, 2020
  8. S. Lonial. Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020
  9. S. Malik. Update on Risk Stratification Model of Smoldering Multiple Myeloma: A Systematic Review. Blood, 2019
  10. A. Lakshman. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer Journal, 2018
  11. S. Rajkumar. Smoldering multiple myeloma.. Blood, 2015
  12. B. Dykstra. PET-CT Has Major Diagnostic Value in the Evaluation of Smoldering Multiple Myeloma. Blood, 2014
  13. M. Dhodapkar. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).. Blood, 2014
  14. K. Neben. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013
  15. M. Mateos. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.. The New England journal of medicine, 2013
  16. R. Kyle. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.. The New England journal of medicine, 2007